Onco Actu du 28 avril 2016

	1. Biologie
The quiet revolutionary: How the co-discovery of CRISPR explosively changed Emmanuelle Charpentier’s life [Nature News & Comment] The microbiologist spent years moving labs and relishing solitude. Then her work on gene-editing thrust her into the scientific spotlight.
	2.11 Etiologie - Alimentation
Does canned food cause cancer? [The Telegraph] Breast Cancer UK has written to the UK subsidiaries of these companies, which include soup giant Campbell’s, for information about the extent of the use of BPA in cans in the UK.
	3.1 Tabac
Doctors warn of big tobacco firms entering e-cigarette market [The Guardian] They expressed concerns that such companies might seek to rehabilitate what has become a “pariah industry” and therefore undermine tobacco control.
Reducing the harm of tobacco, could e-cigarettes be part of the solution? [Cancer Research UK] The report is extensive, covering everything from the science of how our bodies absorb nicotine, through the different types of nicotine replacement therapies available to people, and the impact of tobacco control policies at a population level.
UK doctors urge wide promotion of e-cigs to help smokers quit [Reuters] "This is what tobacco harm reduction is - it reduces the harm from tobacco while recognizing that some people will still use nicotine in other safer forms."
E-cigarettes should be offered to smokers, say doctors [BBC News] It says fears that e-cigarettes are a gateway to smoking are unfounded.
Smokers Urged to Switch to E-Cigarettes by British Medical Group [NY Times] E-cigarettes, he said, “have the potential to help half or more of all smokers get off cigarettes. That’s a huge health benefit, bigger than just about any medical intervention.”
Promote e-cigarettes widely as substitute for smoking says new RCP report [Royal College of Physicians] A new report released today from the Royal College of Physicians, ‘Nicotine without smoke: tobacco harm reduction’ concludes that e-cigarettes are likely to be beneficial to UK public health. Smokers can therefore be reassured and encouraged to use them, and the public can be reassured that e-cigarettes are much safer than smoking.
U.K. Report Advocates E-Cigarettes as Tobacco Substitute [Wall Street Journal] The report, released early Thursday morning in the U.K., rejects several safety arguments marshaled against e-cigarettes in recent years. It argues that smoking tobacco is so deadly that any small potential risk from long-term e-cigarette use is outweighed by their lifesaving effects.
	5. Traitements
Tackling Cancers Of The Immune System With Customized “peptibodies” [Scope Blog] Because the peptibodies are smaller than full-sized antibodies, they penetrate more deeply into tissues. It’s also possible to attach multiple peptides to the antibody portion to allow faster and tighter binding to the cancer cells.
	5.10 Traitements - Essais
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine [Takeda] Pivotal TOURMALINE-MM1 Results Demonstrated that the Addition of Oral Ixazomib to Lenalidomide and Dexamethasone Significantly Extended Progression-Free Survival, with Limited Additional Toxicity in Patients with Relapsed/Refractory Multiple Myeloma.
	5.12 Immunothérapies
Tumor burden, not cancer per cell antigen density or T cell receptor affinity, determine immunotherapy outcome [NIHilist's Immunology] Another conclusion from this study, though not formally tested, is that co-administration of PD1 checkpoint inhibitors may benefit adoptive T cell therapy.
	5.2.2 Pharma - Fusions & Acquisitions
Sanofi offers $9.3B for Medivation--but the biotech isn’t biting [FierceBiotech] People “familiar with the matter” told Reuters that AstraZeneca ($AZN) has already stepped in to offer nearly $10 billion as Medivation’s white knight.
AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer [AbbVie] Long-term data on Rova-T, including overall survival, will be presented at the 2016 ASCO Annual Meeting; Rova-T was recently selected to be included in the Best of ASCO Program.
Sanofi Offers to Acquire Medivation for $ 52.50 Per Share in Cash [Sanofi] – Proposal Would provide Immediate and Certain Value to Medivation’s Shareholders – Combination Would Create Complementary Offerings to Treat Prostate Cancer – Supports Sanofi’s Strategy in Oncology
	5.2.3 Pharma - économie
What’s a billionaire biotech CEO worth? Soon-Shiong’s price is $148M [FierceBiotech] Soon-Shiong’s pay package ranks as one of the biggest ever, and it dwarfs what most of the top-paid execs get. Last year the highest paid CEO in biopharma was Regeneron’s Len Schleifer at $42 million.
Bristol-Myers Squibb Reports First Quarter Financial Results [BMS] “The launch of Opdivo continues to accelerate with data in new cancers, additional indications and continued rapid market adoption. By growing our business and advancing our pipeline, we are successfully executing our growth strategy.”
UBS, MPM team up on $471 million cancer fund to speed drug development [Reuters] A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights.
	5.3 Traitements - FDA, EMA,...
Involving general practitioners in regulatory decisions on medicines [EMA] EMA workshop with general practitioners and family doctors kicks off strengthened collaboration.
	5.3.4 Traitements - AMM (FDA, EMA)
Servier's Lonsurf approved in Europe for colorectal cancer [PharmaTimes] Lonsurf (trifluridine/tipiracil, formerly TAS-102) combines an anticancer drug called trifluridine, which interferes with DNA function, with tipiracil hydrochloride, which maintains blood concentration of the former.
	5.4 Traitements - Economie
Small company offers Medicare cheap version of pricey cancer drug [STAT] Biolyse Pharma maintains that it can supply a version of Xtandi for $3 per 40-milligram tablet, compared with the $69.41 that Medicare paid in 2014.
	5.9.5 AACR - T-cell immunothérapies
AACR Annual Meeting 2016: Can a Universal Adaptor Overcome CAR T-cell Immunotherapy Limitations? [CANCER RESEARCH Catalyst] The adaptors survive for no more than 20 minutes in the blood circulation, which means it is possible to control the rate and extent of tumor cell killing and cytokine release in order to avoid serious adverse effects.
	6.1 Observation
Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk, Penn Study Suggests [UPenn] "Indication Bias" May Explain Link Between Statin Use and Cancer Risk.
	6.10 Politiques
Biden time [Nature News & Commrnt] The US National Cancer Institute has made it clear that it wants to hear recommendations from the community, and has a website dedicated to stimulating participation. This participation need not be restricted to US researchers: international scientists and clinicians should submit recommendations, too.
	6.11 Patients
'My tattoo art helps women feel beautiful after breast cancer' [The Guardian] It was a cold call in 2011 from a woman who had undergone a single mastectomy for breast cancer that took Amy Black’s tattoo career in a new direction.
	6.9 Controverses
What (if anything) does “natural” mean? [Science-Based Medicine] What does the term “natural” mean on a label? Does it mean anything? Should it mean anything? Good questions. And complicated ones, judging from the list of questions the FDA needs your help in answering.
5 Tips For Avoiding P-Value Potholes [Absolutely Maybe] The “bright line” of p-values at 0.05 is taught because the scientific community and journals use it so much. And they use it so much because that’s what they’re taught. The result is a bumpy ride in the literature. Here’s my choice of the top 5 things to keep in mind to avoid p-value potholes.